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Abstract: This article reviews the randomized control trials (RCT’s) that were published in 2007 of emerging pharma-
cotherapies in patients with acute ( 2 weeks), sub-acute (2 to 12 weeks) and chronic ( 12 weeks) stroke. A Medline 
search generated 22 RCT’s in stroke in the year 2007 in the English language. These trials were primarily efficacy studies. 
These included the role of statins (an anti-lipid agent) in reducing post-stroke morbidity and mortality, and decreasing the 
carotid atherosclerotic plaque in middle aged patients at increased risk of cardiovascular disease; glucose-potassium-
insulin infusion in hyperglyceamic acute stroke patients; pioglitazone (an anti-diabetic medication) to reduce recurrence of 
stroke in Type 2 diabetic patients; administration of intra-arterial urokinase (a thrombolytic agent) and the role of laser 
therapy in clot dissolution given that at present there is only one FDA approved thrombolytic agent (r TPA); benefit of 
warfarin (an anticoagulant) in elderly patients with atrial fibrillation in the community; NXY (a free radical trapping 
agent) and minocycline both tested as neuroprotectants; and zoledronate (an intravenous bisphosphonate) to prevent loss 
of bone mineral density of the affected extremity, and finally the role of nicardipine (a Calcium channel blocker) in the 
prevention of vasospasm, and hydrocortisone to prevent hyponatraemia after sub-arachnoid hemorrhage. Finally the role 
of non-pharmacotherapy like stents for patient’s with internal carotid artery dissection with tandem internal carotid and 
middle cerebral artery occlusion and in vertebral artery stenosis.  
Keywords: Randomized control trials, stroke, rehabilitation. 
INTRODUCTION  
  This review focuses on the clinical usefulness of com-
monly used pharmacological agents, readily available to cli-
nicians caring for stroke patients that were assessed in clini-
cal trials published in 2007. 
Hyperlipidaemia and Stroke  
 Title:  Statin treatment withdrawal in ischemic stroke: a 
controlled randomized study. 
  Pretreatment with statins has been shown to reduce brain 
injury in cerebral ischemia [1]. This randomized control 
study, investigated the influence of pretreatment statin and 
its subsequent withdrawal on outcome after acute ischemic 
stroke [2]. Of the 215 patients admitted within 24 hours of a 
hemispheric ischemic stroke, 89 patients on chronic statin 
treatment were randomly assigned either to statin withdrawal 
for the first 3 days after admission (n = 46) or to continue 
receiving atorvastatin 20 mg/day (n = 43). The primary out-
come event was death or dependency (modified Rankin 
Scale [mRS] score > 2) at 3 months. Secondary outcome 
variables were early neurologic deterioration (END) and 
infarct volume at days 4 to 7. In a secondary analysis, out-
come variables were compared with the nonrandomized pa-
tients without previous statin therapy (n = 126). Patients with 
statin withdrawal showed a higher frequency of mRS score > 
2 at the end of follow-up (60.0% vs. 39.0%; p = 0.043), END 
(65.2% vs. 20.9%; p < 0.0001), and greater infarct volume  
 
 
*Address correspondence to this author at the Veterans Affairs Medical 
Center, 921 NE 13
th Street, Oklahoma City OK, USA; Tel: (405) 270- 0501 
Extension 5298; Fax: (405) 270- 1504; E-mail: mhrabadi@gmail.com 
(74 [45, 126] vs. 26 [12, 70] mL; p = 0.002) compared with 
the non-statin-withdrawal group. Statin withdrawal was as-
sociated with a 4.66 (1.46 to 14.91)-fold increase in the risk 
of death or dependency, a 8.67 (3.05 to 24.63)-fold increase 
in the risk of END, and an increase in mean infarct volume 
of 37.63 mL (SE 10.01; p < 0.001) after adjusting for age 
and baseline stroke severity. Compared with patients without 
previous treatment with statins, withdrawal was associated 
with a 19 (1.96 to 184.09)-fold increase in the risk of END 
and an increase in mean infarct volume of 43.5 mL (SE 21.9; 
p = 0.048). The study concluded that statin withdrawal was 
associated with increased risk of death or dependency at 90 
days. Hence, this treatment should be continued in the acute 
phase of ischemic stroke. 
 Title:  Measuring Effects on Intima-Media Thickness: an 
Evaluation of Rosuvastatin (METEOR). 
  Atherosclerosis is often advanced before symptoms ap-
pear and it is unclear whether treatment is beneficial in mid-
dle-aged individuals with a low Framingham risk score 
(FRS) and mild to moderate subclinical atherosclerosis. This 
study assessed whether statin therapy could slow the pro-
gression and/or reduce carotid intima-media thickness 
(CIMT) over 2 years, as assessed with B-mode ultrasound 
for 12 carotid sites [3]. In this randomized, double-blind, 
international, placebo-controlled study 984 individuals were 
enrolled with age (mean, 57 years) as the only coronary heart 
disease risk factor or a 10-year FRS of less than 10%, mod-
est CIMT thickening (1.2-<3.5 mm) with mean CIMT for the 
common carotid artery sites 0.76 ± 0.12 mm and elevated 
LDL cholesterol (mean, 154 mg/dL). Participants received 
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(n=282). Among participants in the rosuvastatin group, the 
mean (SD) baseline LDL cholesterol level of 155 (24.1) 
mg/dL declined to 78 (27.5) mg/dL, a mean reduction of 
49% (P<.001 vs. placebo group). The change in maximum 
CIMT for the 12 carotid sites was -0.0014 (95% CI, -0.0041 
to 0.0014) for the rosuvastatin group vs. 0.0131 (95% CI, 
0.0087-0.0174) for the placebo group (P<.001). The maxi-
mum change in CIMT for the rosuvastatin group was -
0.0038 (95% CI, -0.0064 to -0.0013) mm/y for the common 
carotid artery sites (P<.001), -0.0040 (95% CI, -0.0090 to 
0.0010) for the carotid bulb sites (P<.001), and 0.0039 (95% 
CI, -0.0009 to 0.0088) for the internal carotid artery sites (P 
= .02). The change in mean CIMT for the rosuvastatin group 
for the common carotid artery sites was 0.0004 (95% CI, -
0.0011 to 0.0019) mm/y (P<.001). All p-values were vs. pla-
cebo group. Overall, rosuvastatin was well tolerated with 
infrequent serious adverse cardiovascular events over 2 
years. In middle-aged adults with an FRS of less than 10% 
and evidence of subclinical atherosclerosis, rosuvastatin sig-
nificant reduced the rate of progression of maximum CIMT 
over 2 years vs. placebo. However, long-term trial is needed 
to determine the clinical implications of these findings.  
Treatment of Diabetes Mellitus and Stroke  
 Title:  Effects of pioglitazone in patients with type 2 dia-
betes with or without previous stroke: results from PROac-
tive (PROspective pioglitAzone Clinical Trial In macroVas-
cular Events [4]. 
  Diabetes is an important risk factor for stroke. This 
prospective, double-blind study randomized 5238 patients 
with type 2 diabetes and a history of macrovascular disease 
to either pioglitazone (titrated to 45 mg) or placebo, in 
addition to continuing their diabetes and cardiovascular 
medications [4]. This study evaluated the risk of stroke and 
other cardiovascular outcomes in patients with (n=984) and 
without (n=4254) prior stroke. In patients with previous 
stroke (486 in the pioglitazone group and 498 in the placebo 
group), there was a trend favoring the pioglitazone for the 
primary end points: all-cause death, nonfatal myocardial 
infarction, acute coronary syndrome, and cardiac 
intervention (including coronary artery bypass graft or 
percutaneous coronary intervention), stroke, major leg 
amputation, or bypass surgery or leg revascularization 
(hazard ratio[HR]=0.78, event rate=20.2% pioglitazone vs. 
25.3% placebo; 95% CI=0.60-1.02; P=0.07). Similar results 
were obtained for secondary end points: all-cause death, 
nonfatal myocardial infarction, or nonfatal stroke (HR=0.78, 
event rate=15.6% pioglitazone vs. 19.7% placebo; 95% 
CI=0.58-1.06; P=0.11). Pioglitazone reduced fatal or 
nonfatal stroke (HR=0.53, event rate=5.6% pioglitazone vs. 
10.2% placebo; 95% CI=0.34-0.85; P=0.008) and 
cardiovascular death, nonfatal myocardial infarction, or 
nonfatal stroke (HR=0.72, event rate = 13.0% pioglitazone 
vs. 17.7% placebo; 95% CI=0.52-1.00; P=0.0467). Higher 
event rates were observed in patients with prior stroke 
compared with those without prior stroke. In patients without 
prior stroke no treatment benefit was observed. Thus in the 
subgroup analysis of this study, pioglitazone was effective in 
secondary not in primary stroke prevention in patients with 
type 2 diabetes.  
 Title:  Glucose-potassium-insulin infusions in the man-
agement of post-stroke hyperglycaemia: the UK Glucose 
Insulin in Stroke Trial (GIST-UK). 
  Hyperglycaemia after an acute stroke is a common find-
ing and has been associated with an increased risk of death. 
This study set out to determine whether treatment with glu-
cose-potassium-insulin (GKI) infusions to maintain eugly-
caemia immediately after the acute event reduces death at 90 
days [5]. Patients presenting within 24 h of stroke onset and 
with admission plasma glucose concentration between 6.0-
17.0 mmol/L were randomly assigned to receive variable-
dose-insulin GKI (intervention) or saline (control) as a con-
tinuous intravenous infusion for 24 h. The aim was to main-
tain capillary glucose at 4-7 mmol/L in the GKI group, with 
no glucose intervention in the control group. The primary 
outcome was death at 90 days, and the secondary endpoint 
was avoidance of death or severe disability at 90 days. The 
trial was powered to detect a mortality difference of 6% 
(sample size 2355), with 83% power, at the 5% two-sided 
significance level. This study was stopped after 933 patients 
were recruited due to slow enrollment. For the intention-to-
treat data, there was no significant reduction in mortality at 
90 days (GKI vs. control: odds ratio 1.14, 95% CI 0.86-1.51, 
p=0.37). There were no significant differences for secondary 
outcomes. In the GKI group, overall mean plasma glucose 
and mean systolic blood pressure were significantly lower 
than in the control group (mean difference in glucose 0.57 
mmol/L, p<0.001; mean difference in blood pressure 9.0 
mmHg, p<0.0001). The study concluded that despite signifi-
cant reduction in the plasma glucose concentrations and 
blood pressure in the GKI group, these interventions did not 
reduce death or disability rates. Thus maintaining euglycae-
mia by GKI infusion may have a very small effect in reduc-
ing death or disability, given that it could not be seen in 
>900 subjects studied. 
Thrombolytics and Stroke: 
 Title:  A pilot study of dual treatment with recombinant 
tissue plasminogen activator and uric acid in acute ischemic 
stroke. 
  Uric acid (UA) has been shown to increase the neuropro-
tective effects of recombinant tissue plasminogen activator 
(rt-PA) in experimental ischemia [6]. In patients with stroke, 
increased UA levels have been linked to better stroke recov-
ery [7], but the clinical safety of dual administration of UA 
and rt-PA is unknown. This was assessed in a double-blind 
study [8]. Patients were randomized to an intravenous solu-
tion of 500 mL of 5% mannitol/0.1% lithium carbonate (con-
trol group, n=8) or 500 or 1000 mg of UA (n=16). Safety end 
points at day 90, lipid peroxidation (serum malondialde-
hyde), and serum kinetics of UA were established. Twenty-
four patients with stroke were treated with rt-PA within 
mean (SD) 133 (35) minutes of clinical onset (admission 
National Institutes of Health Stroke Scale score mean [SD] 
11 [7], age 71 [10.6] years, 71% males). Levels of UA de-
creased in the control group and increased for 24 hours in the 
high dose UA group, which also had lower levels of 
malondialdehyde at day 5. Mortality (12.5%), symptomatic 
central nervous system bleeding (0%), and outcome at day 
90 were similar in the 2 treatment arms; one patient in the 
high-dose UA group had a mild gouty episode. Administra-
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and prevented an early fall of UA in serum in patients treated 
with rt-PA within 3 hours of stroke onset. However, there 
were no beneficial clinical effects between the 2 groups. The 
clinical efficacy of dual administration of exogenous UA and 
rt-PA needs further investigation in a larger acute stroke 
trial.  
Title: The NeuroThera Effectiveness and Safety Trial-1 
(NEST-1). 
  This study evaluated the safety and effectiveness of the 
NeuroThera Laser System (NTS) to improve 90-day out-
comes in ischemic stroke patients treated within 24 hours 
from stroke onset. The NeuroThera Laser System uses infra-
red laser technology that involves photobiostimulation 
(which is increased adenosine triphosphate
 [ATP] formation 
on stimulation of the copper center CuA of the cytochrome c 
oxidase, the primary mitochondrial chromophore to 808 nm 
energy delivered by NTS) and has shown significant and 
sustained beneficial effects in animal models of ischemic 
stroke [9]. In this prospective, intention-to-treat, multicenter, 
international, double-blind, trial, 120 acute ischemic stroke 
patients were randomized in a 2:1 ratio, with 79 patients in 
the active treatment group and 41 in the sham (placebo) con-
trol group [10]. The patients had baseline stroke severity 
scores of 7 to 22, as measured by National Institutes of 
Health Stroke Scale (NIHSS). Patients who received tissue 
plasminogen activator were excluded. The primary outcome 
measure identified as successful treatment, was defined as a 
complete recovery at day 90 (NIHSS 0 to 1), or a decrease in 
NIHSS score of at least 9 points (day 90 versus baseline), 
and was tested as a binary measure (bNIH). Secondary out-
come measures included modified Rankin Scale mRS, 
Barthel Index, and Glasgow Outcome Scale at 90 days after 
treatment. Primary statistical analyses performed with the 
Cochran-Mantel-Haenszel rank test , were stratified by base-
line NIHSS score or by time to treatment for the bNIH and 
mRS. The mean time to treatment was >16 hours (median 
time to treatment 18 hours for active and 17 hours for con-
trol). Time to treatment ranged from 2 to 24 hours. More 
patients (70%) in the active treatment group had successful 
outcomes than did controls (51%), as measured prospec-
tively on the bNIH (P=0.03 stratified by severity and time to 
treatment; P=0.048 stratified only by severity). Similarly, 
more patients (59%) had successful outcomes than did con-
trols (44%) as measured at 90 days as a binary mRS score of 
0 to 2 (P=0.03 stratified by severity and time to treatment; 
P=0.04 stratified only by severity). Also, more patients in the 
active treatment group had successful outcomes than con-
trols as measured by the change in mean NIHSS score from 
baseline to 90 days (P=0.02 stratified by time to treatment) 
and the full mRS ("shift in Rankin") score (P=0.02 stratified 
by severity and time to treatment; P=0.03 stratified only by 
severity). Mortality rates and serious adverse events (SAEs) 
did not differ significantly (8.9% and 25.3% for active 9.8% 
and 36.6% for control, respectively, for mortality and SAEs). 
The NEST-1 study indicated that infrared laser therapy to be 
a safe and effective treatment for ischemic stroke in humans 
when initiated within 24 hours of stroke onset. A larger con-
firmatory trial to determine safety and effectiveness more 
conclusively is warranted.  
 Title:  Intra-arterial infusion of urokinase within 6 hours 
of middle cerebral artery stroke: the Middle cerebral artery 
Embolism Local fibrinolytic intervention Trial (MELT Ja-
pan).  
  The MELT Japan was organized to determine the safety 
and clinical efficacy of intra-arterial infusion of urokinase 
(UK) within 6 hours of stroke onset [11]. Patients with 
ischemic stroke presenting within 6 hours of onset and dis-
playing occlusions of the M1 or M2 portion of the middle 
cerebral artery on carotid angiography were randomized to 
the UK or control groups. The modified Rankin Scale 
(mRS), National Institutes of Health Stroke Scale, and 
Barthel Index were used to assess clinical outcome. The In-
dependent Monitoring Committee recommended stopping 
the trial after approval of intravenous infusion of recombi-
nant tissue plasminogen activator in Japan. A total of 114 
patients underwent randomization, 57 patients in each group. 
Background characteristics were comparable between the 2 
groups. The primary end point of favorable outcome (mRS 0 
to 2) at 90 days was numerically higher in the UK-treated 
than in the control group (49.1% and 38.6%, OR: 1.54, 95% 
CI: 0.73 to 3.23) but was not statistical (P=0.345). Excellent 
functional outcome (mRS 0 to 1) at 90 days, a preplanned 
secondary end point, was more frequent in the UK than in 
the control group (42.1% and 22.8%, P=0.045, OR: 2.46, 
95% CI: 1.09 to 5.54). There were also more patients with 
National Institutes of Health Stroke Scale 0 or 1 at 90 days in 
the UK group than the control group (P=0.017). The 90-day 
cumulative mortality was 5.3% in the UK group and 3.5% in 
the control group (P=1.000), and intracerebral hemorrhage 
within 24 hours of treatment occurred in 9% and 2%, respec-
tively (P=0.206). Since this trial was stopped early it was not 
sufficiently powered to provide more definitive conclusions. 
The primary end point did not reach statistical significance. 
However, the secondary analyses showed that intra-arterial 
thrombolysis to have the potential to increase excellent func-
tional outcome. The MELT study design paralleled the 
PROACT II study [12]. However, in the PROACT II study 
the similar primary end point favored the UK group, which 
was not reported in the MELT study. There are several rea-
sons suggested for this failure to show efficacy in this study. 
First, because this trial was terminated prematurely, the 
number of patients enrolled was too low to detect any differ-
ence between the UK and
 control groups in the primary end 
point. Second, there were 38.6% of
 patients with mRS score 
0 to 2 in the control group. Thus the patients
 in the MELT 
Japan study had milder strokes. Likewise, the median
 NIHSS 
score was lower than in the PROACT studies. Finally, the 
MELT Japan
  prohibited mechanical clot disruption except 
for the guide-wire
  technique to examine the effect of UK 
itself. The re-canalization rate in this study
 was 73.7% which 
was better than 66% reported in the PROACT II study, 
which prohibited any mechanical procedure [12]. Therefore, 
mechanical
 fibrinolysis in this study may have be one of the 
reasons for the present favorable
 re-canalization rate. 
Antiplatelets and Stroke 
 Title:  Medium intensity oral anticoagulants versus aspi-
rin after cerebral ischemia of arterial origin [The Euro-
pean/Australasian Stroke Prevention in Reversible Ischemia 
Trial (ESPRIT)]: a randomized controlled trial.  
  Oral anticoagulants are better than aspirin for secondary 
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ischemia in patients with non-rheumatic atrial fibrillation 
[13]. ESPRIT aimed to determine whether medium intensity 
of oral anticoagulation with was more effective than aspirin 
in preventing future vascular events in patients with transient 
ischemic attack or minor stroke of presumed arterial origin 
[14]. In this international, multi-centre open label trial, pa-
tients within 6 months after a transient ischemic attack or 
minor stroke of presumed arterial origin were randomly as-
signed to either anticoagulants (target INR range 2.0-3.0; 
n=536) or aspirin (30-325 mg daily; n=532). The primary 
outcome was the composite of death from all vascular 
causes, non-fatal stroke, non-fatal myocardial infarction, or 
major bleeding complication, whichever occurred first. In a 
post hoc analysis anticoagulants were compared with the 
combination of aspirin and dipyridamole (200 mg twice 
daily). The primary analysis was by intention to treat. The 
anticoagulant versus aspirin comparison of ESPRIT was 
prematurely ended because ESPRIT had previously showed 
that that the combination of aspirin and dipyridamole was 
superior to aspirin alone. ESPRIT had a mean follow-up of 
4.6 years (SD 2.2). The mean achieved INR was 2.57 (SD 
0.86). A primary outcome event occurred in 99 (19%) pa-
tients on anticoagulants and in 98 (18%) patients on aspirin 
(hazard ratio [HR] 1.02, 95% CI 0.77-1.35). The HR for 
ischemic events was 0.73 (0.52-1.01) and for major bleeding 
complications was 2.56 (1.48-4.43) in the anticoagulation 
group. The HR for the primary outcome event comparing 
anticoagulants with the combination treatment of aspirin and 
dipyridamole was 1.31 (0.98-1.75). This study showed that 
medium intensity oral anticoagulation (target INR range 2.0-
3.0) was equally effective as aspirin for secondary preven-
tion after transient ischemic attack or minor stroke of arterial 
origin. Increased bleeding complications in the oral antico-
agulation group offset its protective effect against ischemic 
events.  
Treatment of Atrial Fibrillation and Stroke  
 Title:  Warfarin versus aspirin for stroke prevention in an 
elderly community population with atrial fibrillation (the 
Birmingham Atrial Fibrillation Treatment of the Aged Study, 
[BAFTA]): a randomised controlled trial.  
  Warfarin reduces recurrent stroke risk in patients with 
atrial fibrillation [15]. Whether this benefit outweighs the 
increased risk of bleeding in elderly patients is unknown. 
This study assessed whether warfarin reduced risk of major 
stroke, arterial embolism, or other intracranial hemorrhage 
compared with aspirin (ASA) in elderly patients [16]. Some 
973 patients aged 75 years or over (mean age 81.5 years, SD 
4.2) with atrial fibrillation were recruited from primary care 
and randomly assigned to either warfarin (target international 
normalized ratio 2-3) or aspirin (75 mg per day). Follow-up 
was for a mean of 2.7 years (SD 1.2). The primary endpoint 
was fatal or disabling stroke (ischemic or hemorrhagic), in-
tracranial hemorrhage, or clinically significant arterial embo-
lism. Analysis was by intention to treat. There were 24 pri-
mary events (21 strokes, two intracranial hemorrhages, and 
one systemic embolus) in people assigned to the warfarin 
group and 48 primary events (44 strokes, one intracranial 
hemorrhage, and three systemic emboli) in people assigned 
to aspirin (yearly risk 1.8%vs 3.8%, relative risk 0.48, 95% 
CI 0.28-0.80, p=0.003; absolute yearly risk reduction 2%, 
95% CI 0.7-3.2). The annual risk of extra-cranial hemor-
rhage was 1.4% (warfarin) versus 1.6% (aspirin). This study 
suggests anticoagulation therapy benefits people aged over 
75 who have atrial fibrillation, unless there are contraindica-
tions to its use or the patient decides that the hemorrhagic 
risk outweighs its benefit.  
Neuroprotection and Stroke 
 Title:  Cerebral Hematoma and NXY Treatment trial 
(CHANT).  
  NXY-059 is a free radical-trapping agent which neuro-
protects by preventing brain tissue oxidation in acute 
ischemic stroke. This study investigated the safety of NXY-
059 in patients with intracerebral hemorrhage (ICH) [17]. 
Some 607 patients within 6 hours of acute ICH received 
2270 mg intravenous NXY-059 over 1 hour and then up to 
960 mg/h over the subsequent 71 hours (n=300), or matching 
placebo (n=303), in addition to standard care. The primary 
outcomes for safety were: the mortality and the frequency of 
adverse clinical events. Other tests for adverse events in-
cluded a change from baseline for serum potassium, intrac-
ranial hematoma volume on neuroimaging, and electrocaar-
diographic changes during infusion period. The overall dis-
tribution of disability scores on the modified Rankin Scale 
(mRS) and the Barthel index were also studied. Treatment 
groups were well matched for prognostic variables including 
Glasgow Coma Scale, risk factors, and age. The mean Na-
tional Institute of Health Stroke Scale score on admission 
was 14 in both groups. The baseline hemorrhage volume was 
22.4±20.1 mL in the NXY-059 group and 23.3±22.8 mL in 
the placebo group (mean±SD). Most hemorrhages were re-
lated to hypertension or anticoagulant use. Mortality was 
similar in both groups: 20.3% for NXY-059 and 19.8% for 
placebo-treated patients. The incidence of adverse event was 
the same for both groups; however, the proportion of serious 
adverse events was slightly higher in the NXY-059 group. 
Serum potassium fell transiently in both groups, but was 
lower in the NXY-059 group. No differences in 3-month 
functional disability, or neurological deficit scores were 
noted. The odds ratio for an improved outcome in 3-month 
mRS scores in the NXY-059 group was 1.01 (95% CI 0.75, 
1.35). NXY-059 given within 6 hours of acute ICH was to 
found a good safety and tolerability profile, with no adverse 
effect on clinical outcomes but also no benefits. 
 Title:  Stroke-Acute ischemic NXY Treatment (SAINT II) 
Trial Investigator.  
  The free-radical-trapping agent NXY-059 had shown 
promise as a neuroprotectant in the Stroke-Acute Ischemic 
NXY Treatment I (SAINT I) trial [18] by reducing disability 
when given to patients who had acute ischemic stroke. The 
current study sought to confirm this efficacy in a second, 
larger trial [19]. Some 3,306 patients with acute ischemic 
stroke were randomized in a double-blind trial to receive a 
72-hour infusion of intravenous NXY-059 or placebo within 
6 hours after the onset of stroke symptoms. The primary end 
point was the distribution of disability scores at 90 days on 
the modified Rankin scale (mRS). The National Institute of 
Health Stroke Scale and the Barthel Index were secondary 
end points. The efficacy analysis was based on 3195 pa-
tients. Demographic variables were well balanced between 
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did not differ between the NXY-059 treated (1588 patients) 
and the placebo (1607) group; P=0.33 by the Cochran-
Mantel-Haenszel test; odds ratio for limiting disability, 0.94; 
95% confidence interval [CI], 0.83 to 1.06). Analysis of 
categorized scores on the modified Rankin scale confirmed 
the lack of benefit: the odds ratio for the three stratified 
modified Rankin scale scores of 0 to 1 versus 2 to 3 versus 4 
to 6 was 0.92 (95% CI, 0.80 to 1.06). There was no evidence 
of efficacy for any of the secondary end points. Mortality 
was equal in the two groups, and adverse-event rates were 
similar. Among patients treated with alteplase, there was no 
difference between the NXY-059 group and the placebo 
group in the frequency of symptomatic or asymptomatic 
hemorrhage. Thus NXY-059 was ineffective for the treat-
ment of acute ischemic stroke within 6 hours after the onset 
of symptoms. This study like several earlier phase III trials 
of neuroprotection has failed to live up to the expectations 
created by preclinical testing in animal models. Several rea-
sons have been cited for these disappointing human results: 
a) animal models may not mimic human ischemic stroke; b) 
preclinical trials have administered the drug prior to or 
within a few minutes of lesion being made; c) lack of ran-
domization; d) lack of in vitro efficacy in human tissue using 
cell cultures or brain slices; e) lack of in vivo studies of neu-
roprotectants distribution in the normal and ischemic brain; 
and f) lack of use of imaging techniques in phase II and III 
neuroprotectant studies to identify the extent of the pneum-
bra, its target site.  
 Title:  Minocycline treatment in acute stroke: an open-
label, evaluator-blinded study. 
  Minocycline has a neuroprotective effect in ischemic 
animal models [20]. This study assessed the effect of mino-
cycline treatment in human acute ischemic stroke [21]. In 
this open-label, evaluator-blinded study, Minocycline in a 
dosage of 200 mg was administered orally for 5 days starting 
within 6 to 24 hours after onset of stroke. The outcome 
measures were: NIH Stroke Scale (NIHSS), modified Rankin 
Scale (mRS), and Barthel Index (BI). The primary objective 
was to compare changes from baseline to day 90 in NIHSS 
in the minocycline group vs. placebo. Of the 152 patients 
enrolled in the study, 74 received minocycline treatment and 
77 placebo. NIHSS and mRS were significantly lower and 
BI scores were significantly higher in minocycline-treated 
patients. This pattern was already apparent on day 7 and day 
30 of follow-up. Deaths, myocardial infarctions, recurrent 
strokes, and hemorrhagic transformations during follow-up 
were similar in both groups. This study suggests minocycline 
to be of potential functional benefit in acute ischemic stroke. 
Despite minocycline being effective in ischemic stroke pa-
tients, the small sample size and open-label study indicate 
the need for a large randomized control trial. 
Surgery for Stroke  
 Title:  Long-term outcome after angioplasty and stenting 
for symptomatic vertebral artery stenosis compared with 
medical treatment in the Carotid and Vertebral Artery 
Transluminal Angioplasty Study (CAVATAS): a randomized 
trial.  
  The long-term outcome of endovascular intervention 
compared with best medical management of patients with 
symptomatic vertebral artery stenosis is not known. In this 
international, multi-center study, 16 patients with sympto-
matic vertebral artery stenosis were randomized in equal 
proportions to receive endovascular therapy (balloon an-
gioplasty or stenting) or best medical treatment alone [22]. 
An independent neurologist followed up the patients for 8 
years. Endovascular intervention was technically successful 
in all 8 patients and there were no deaths or strokes in any 
arterial territory within the first 30 days. During a mean fol-
low-up period of 4.7 years, no patient in either treatment 
group experienced a vertebrobasilar territory stroke, but 3 
patients in each treatment arm died of myocardial infarction 
or carotid territory stroke, and 1 endovascular patient had a 
nonfatal carotid territory stroke. The study concluded that 
patients with vertebral artery stenosis were more likely to 
have carotid territory stroke and myocardial infarction during 
follow-up than to have recurrent vertebrobasilar stroke. This 
trial failed to show a benefit of endovascular treatment for 
vertebral artery stenosis. The reason for lack of benefit of 
endovascular treatment may mainly be due to the small 
numbers of patients included in the study. Larger random-
ized trials would be required to determine whether vertebral 
artery stenting is justified in patients at higher risk of verte-
brobasilar stroke. This study highlights that in patients with 
vertebral artery stenosis the focus should be on global reduc-
tion of vascular risk factors which in turn would prevent fur-
ther carotid territory stroke and myocardial infarction.  
 Title:  Stent-assisted endovascular thrombolysis versus 
intravenous thrombolysis in internal carotid artery dissec-
tion with tandem internal carotid and middle cerebral artery 
occlusion.  
  Spontaneous dissection of the internal carotid artery 
(ICA) is one of the main causes of ischemic stroke in young 
patients, and anticoagulation is its recommended treatment 
[23]. Tandem ICA and middle cerebral artery occlusions 
independently predict poor outcome after intravenous 
thrombolysis. Recently recanalization of ICA dissection by 
stent-assisted angioplasty has recently been proposed when 
anticoagulation fails to prevent a new ischemic event. Con-
secutive patients presenting within 3 hours of symptom onset 
with tandem internal carotid and middle cerebral artery oc-
clusion with ICA dissection, who were eligible for intrave-
nous thrombolysis, were randomized to either endovascular 
stent-assisted thrombolysis (n=6) or intravenous recombinant 
tissue-type plasminogen activator (rtPA) when an endovas-
cular therapist was unavailable (n=4) [24]. National Insti-
tutes of Health Stroke Scale (NIHSS) scores were obtained 
at baseline and after 24 hours. The modified Rankin Scale 
score (mRS) was used to assess outcomes at 3 months. Arte-
rial recanalization was assessed by magnetic resonance im-
aging. The mean NIHSS scores before treatment were high 
(17 and 16, respectively) in the 2 groups. In the endovascular 
group, all patients achieved middle cerebral artery recanali-
zation with subsequent dramatic improvement versus only 1 
patient with middle cerebral artery recanalization in the in-
travenous rtPA group. At 3 months, 4 patients in the endo-
vascular group had a favorable outcome (mRS score=0). In 
the intravenous rtPA group, 3 patients had a poor outcome 
(mRS score  3). Thus endovascular stent-assisted throm-
bolysis was found to be a promising treatment option in tan-
dem internal carotid and middle cerebral artery occlusion 
with ICA dissection and compared favorably to intravenous 
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  Unfortunately, the small numbers of individuals studied 
in these tests of surgical interventions for stroke make confi-
dent conclusions impossible, despite the potential interest of 
these approaches. 
Stroke and Subarachnoid Hemorrhage (SAH) 
 Title:  Effect of nicardipine prolonged-release implants 
on cerebral vasospasm and clinical outcome after severe 
aneurysmal subarachnoid hemorrhage (SAH): a prospective, 
randomized, double-blind phase IIa study.  
  This study investigated the efficacy of nicardipine pro-
longed-release implants (NPRIs) on cerebral vasospasm and 
clinical outcome after severe subarachnoid hemorrhage 
(SAH) [25]. Thirty-two patients with severe SAH undergo-
ing aneurysm clipping within 48 hours at a single center 
were randomized: 16 patients received NPRIs implanted into 
the basal cisterns in direct contact to the exposed proximal 
blood vessels; in 16 control patients, the basal cisterns were 
opened and washed out only without leaving implants. An-
giography was performed preoperatively and at day 8±1. 
Computed tomography imaging analyzed the incidence of 
territorial infarcts unrelated to surgery. Clinical outcome was 
assessed using the modified Rankin (mRS) and National 
Institute of Health Stroke (NIHSS) scales. The incidence of 
angiographic vasospasm in proximal vessel segments was 
significantly reduced after implantation of NPRIs (73% con-
trol versus 7% NPRIs). Computed tomography scans re-
vealed a lower incidence of delayed ischemic lesions (47% 
control versus 14% NPRIs). The NPRI group demonstrated 
more favorable mRS and NIHSS scales as well as a signifi-
cantly fewer deaths (38% control versus 6% NPRIs). Thus 
NPRIs implants reduced the incidence of cerebral vasospasm 
and delayed ischemic deficits and improved clinical outcome 
after severe SAH.  
 Title:  A randomized controlled trial of hydrocortisone 
against hyponatremia in patients with aneurysmal subarach-
noid hemorrhage.  
  Hyponatremia is common after aneurysmal subarachnoid 
hemorrhage (SAH). This is caused by the cerebral salt wast-
ing syndrome, which induces osmotic diuresis and decreases 
blood volume, contributing to symptomatic cerebral vaso-
spasm (SCV). Hypervolemic therapy in the presence of flu-
drocortisones has been effective in preventing SCV than by 
itself alone [26]. Seventy-one SAH patients were randomly 
assigned after surgery to treatment with either a placebo 
(n=36) or 1200 mg/d of hydrocortisone (n=35) within 72 
hours for 10 days and tapered thereafter [27]. Both groups 
underwent hypervolemic therapy. The primary end point was 
the prevention of hyponatremia. Hydrocortisone prevented 
excess sodium excretion (P=0.04) and urine volume 
(P=0.04). Hydrocortisone maintained the targeted serum 
sodium level throughout the 14 days (P<0.001), and allowed 
for lower sodium and fluid (P=0.007) supplementation. Hy-
drocortisone kept the plasma osmolarity normal (P<0.001). 
SCV occurred in 9 patients (25%) in the placebo group and 
in 5 (14%) in the hydrocortisone group. Thus hydrocortisone 
overcame excess natriuresis and prevented hyponatremia. 
Although no difference in SCV was found, hydrocortisone 
supported hypervoluemic therapy was more effective than 
hypervolemic therapy alone in treating SAH induced hypo-
natremia.  
 Title:  Care management of poststroke depression: a ran-
domized, controlled trial. Poststroke depression is a preva-
lent and disabling disorder.  
  This study determined the effectiveness of the “Activate-
Initiate-Monitor” care management program for the treat-
ment of poststroke depression [28]. The “Activate-Initiate-
Monitor” is a care management program that comprises of 
“Activation” making the patient recognize his depression 
symptoms and accept treatment, “Initiation” of making the 
patient take his antidepressant medication, and “Monitoring” 
to make adjustments to his antidepressant medication. Thus 
this was a proactive intervention in the management of post-
stroke depression. In this prospective, randomized, outcome-
blinded trial of 188 ischemic stroke survivors identified at 
the time of admission to one of 4 Indianapolis hospitals, de-
pression screening and enrollment occurred between 1 and 2 
months post-stroke. Usual care subjects (n=93) received 
nondepression-related education and were prescribed antide-
pressants at the discretion of their provider. The primary 
outcome measure was depression response, defined as a 
Hamilton Depression Inventory score <8 (remission) or a 
decrease from baseline of at least 50% at 12 weeks. The in-
tervention and usual care groups had similar key baseline 
measures. Both depression response (51% versus 30%, 
P=0.005) and remission (39% versus 23%, P=0.01) occurred 
more frequently in the Activate-Initiate-Monitor intervention 
than in the usual care group. This difference in depression 
scores was present by 6 weeks and persisted through the 12-
week assessment. Serious adverse events did not differ be-
tween the 2 groups. The Activate-Initiate-Monitor care man-
agement model was more effective than usual care in im-
proving depression outcome measures in patients with post-
stroke depression.  
 Title:  Motivational interviewing early after acute stroke: 
a randomized, controlled trial.  
  The purpose of this study was to determine whether mo-
tivational interviewing, a patient-centered counseling tech-
nique, can benefit patient’s mood 3 months after stroke [29]. 
In this single-center, open, randomized, controlled trial on a 
stroke unit, 411 consecutive patients who were over 18 years 
of age and who did not have severe cognitive and communi-
cation problems were enrolled with 28 days of their acute 
stroke. Patients in the intervention group received 4 individ-
ual, weekly sessions of motivational interviewing with a 
trained therapist in addition to usual stroke care. The primary 
outcome was the proportion of patients with normal mood at 
3 months poststroke measured by the 28-item General Health 
Questionnaire (normal, <5; low > or=5) using a mailed ques-
tionnaire. Eighty-one of 207 (39.1%) patients in the control 
group and 100 of 204 (49.0%) patients in the intervention 
group had normal mood at follow up. A significant benefit of 
motivational interviewing over usual stroke care (OR: 1.60, 
95% CI: 1.04 to 2.46, P=0.03) was found, suggesting that 
motivational interviewing leads to an improvement in pa-
tients' mood 3 months after stroke. 
Stroke and Bone Loss 
 Title:  A single infusion of zoledronate prevents bone loss 
after stroke.  
  Hip fractures are common in stroke patients due to lim-
ited mobility leading to disuse osteoporosis. Patients with Randomized Clinical Stroke Trials in 2007  The Open Neurology Journal, 2008, Volume 2    61 
moderate stroke severity at the time of hospital discharge 
have the most fractures. This proof-of-concept study evalu-
ated the efficacy of a single infusion of zoledronate, an in-
travenous bisphosphonate, in preserving hip bone density 
after stroke [30]. In this double-blind, placebo-controlled, 
clinical trial, 27 hemiplegic patients (6 women, 21 men) 
within 35 days of acute stroke were randomized to receive 4 
mg of intravenous zoledronate (n=14) or placebo (n=13). 
Both groups received calcium and vitamin D supplements. 
The primary outcome measure was the change in bone min-
eral density (BMD) at the hemiplegic hip during the year of 
investigation measured by dual energy x-ray absorptiometry 
(Lunar Prodigy). Mean total hip BMD was unchanged in the 
hemiplegic hip of the zoledronate group (mean 0.0% 
change), whereas in the placebo group the total hip BMD 
decreased by -5.5%, with the greatest bone loss observed in 
the trochanteric subregion (mean, -8.1%). On the unaffected 
side the mean change in total hip BMD was +1.0% with 
zoledronate versus a mean change of -2.7% without. Re-
peated measures ANOVA confirmed the significance of the 
differences between groups at both hips (hemiplegic, 
P<0.001; unaffected, P=0.002). The treatment was generally 
well tolerated. The study concluded that after a single infu-
sion of zoledronate, patients with moderately severe strokes 
were protected from the harmful effects of hemiplegia on hip 
bone density for at least 1 year. Neither group of patients had 
any falls or fractures recorded during the study period.  
Stroke and Deep Vein Thrombosis  
 Title:  Prevention of venous thromboembolism after acute 
ischemic stroke (PREVAIL Study).  
  Low molecular weight heparin or unfractionated heparin 
is recommended for prophylaxis of venous thromboem-
bolism in patients with acute ischemic stroke. This study 
aimed to compare which treatment regimen - enoxaparin or 
unfractionated heparin - was better for patients with acute 
ischemic stroke [31]. Some 1762 patients with acute 
ischemic stroke who were unable to walk unassisted were 
randomly assigned within 48 h of symptoms to receive either 
enoxaparin 40 mg subcutaneously once daily or unfraction-
ated heparin 5000 U subcutaneously every 12 h for 10 days 
(range 6-14). Patients were stratified by National Institutes 
of Health Stroke Scale (NIHSS) score (severe stroke 14, 
less severe stroke <14). The primary efficacy endpoint was 
the composite of symptomatic or asymptomatic deep vein 
thrombosis, symptomatic pulmonary embolism, or fatal pul-
monary embolism. Primary safety endpoints were: sympto-
matic intracranial hemorrhage, major extracranial hemor-
rhage, and all-cause mortality. Enoxaparin (n=666) reduced 
the risk of venous thromboembolism by 43% compared with 
unfractionated heparin (n=669) (68 [10%] vs. 121 [18%]; 
relative risk 0.57, 95% CI 0.44-0.76, p=0.0001; difference -
7.9%, -11.6 to -4.2); this reduction was consistent for pa-
tients with an NIHSS score of 14 or more (26 [16%] vs. 52 
[30%]; p=0.004) or less than 14 (42 [8%] vs. 69 [14%]; 
p=0.004). The occurrence of any bleeding was similar with 
enoxaparin (69 [8%]) or unfractionated heparin (71 [8%]; 
p=0.83). The frequency of symptomatic intracranial and ma-
jor extracranial hemorrhage was small and similar between 
groups (enoxaparin 11 [1%] vs. unfractionated heparin 6 
[1%]; p=0.23). No difference was noted for symptomatic 
intracranial hemorrhage between groups (4 [1%] vs. 6 [1%], 
respectively; p=0.55); and the rate of major extracranial 
(gastrointestinal) bleeding was higher with enoxaparin than 
with unfractionated heparin (7 [1%] vs. 0; p=0.015). The 
study concluded that for patients with acute ischemic stroke, 
enoxaparin was preferable to unfractionated heparin for ve-
nous thromboembolism prophylaxis because of its superior 
clinical benefit to risk ratio and convenience of once daily 
administration.  
Transient Ischemic Attack Treatment  
 Title:  Effect of urgent treatment of transient ischemic 
attack and minor stroke on early recurrent stroke (EXPRESS 
study): a prospective population-based sequential compari-
son.  
  The risk of recurrent stroke is up to 10% in the week af-
ter a transient ischemic attack (TIA) or minor stroke [32]. 
This risk has been reported to be reduced by 80 to 90% by 
urgently initiating existing treatments such as antiplatelet 
aspirin or clopidogrel, anticoagulant, statin, and an ACE 
inhibitor [33], but in the absence of evidence for early exist-
ing treatment many health-care facilities have made little 
provision to offer such treatment. This study aimed to deter-
mine the effect of rapid implementation of such an existing 
treatment after TIA and minor stroke in patients who are not 
admitted directly to the hospital [34]. In this prospective be-
fore versus after (phase 1: April 1, 2002, to Sept 30, 2004 ; 
phase 2: Oct 1, 2004, to March 31, 2007) study of the effect 
of more urgent assessment and immediate treatment in the 
clinic, rather than in primary care, on all patients with TIA or 
minor stroke not admitted directly to a hospital. This study 
was nested within a population-based study of all TIA and 
stroke in a specific catchment area in southern England (Ox-
ford Vascular Study; OXVASC). The primary outcome was 
the risk of stroke within 90 days of first seeking medical 
attention. Of the 1278 patients in OXVASC who presented 
with TIA or mild stroke (634 in phase 1 and 644 in phase 2), 
607 were referred or presented directly to hospital, 620 were 
referred for outpatient assessment, and 51 were not referred. 
Of the outpatient referrals to the study clinic (95%, n=591) 
baseline characteristics and delays in seeking medical atten-
tion were similar in both periods, but median delay to as-
sessment in the study clinic fell from 3 (IQR 2-5) days in 
phase 1 to less than 1 (0-3) day in phase 2 (p<0.0001), and 
median delay to first prescription of treatment fell from 20 
(8-53) days to 1 (0-3) day (p<0.0001). The 90-day risk of 
recurrent stroke in the patients referred to the study clinic 
was 10.3% (32/310 patients) in phase 1 and 2.1% (6/281 
patients) in phase 2 (adjusted hazard ratio 0.20, 95% CI 
0.08-0.49; p=0.0001). This reduction in risk of recurrent 
stroke was independent of age and sex. Early initiation of 
existing treatment did not increase the risk of intracerebral 
hemorrhage or other bleeding. Thus early initiation of exist-
ing treatments after TIA or minor stroke was associated with 
an 80% reduction in the risk of early recurrent stroke. The 
beneficial results of early treatment in this study are an eye 
opener for the need for service provision and public educa-
tion about TIA and minor stroke.  
 Title:  Fast assessment of stroke and transient ischemic 
attack to prevent early recurrence (FASTER): a randomized 
controlled pilot trial.  62    The Open Neurology Journal, 2008, Volume 2  Rabadi and Blass 
  Patients with transient ischemic attack (TIA) or minor 
stroke are at high immediate risk of stroke. In this study 392 
patients with TIA or minor stroke were randomly assigned 
within 24 h of symptom onset to clopidogrel (300 mg load-
ing dose then 75 mg daily; 198 patients) or placebo (194 
patients), and simvastatin (40 mg daily; 199 patients) or pla-
cebo (193 patients) [35]. All patients were also given aspirin 
and were followed for 90 days. Analysis was by intention to 
treat. The primary outcome was total stroke (ischemic and 
hemorrhagic) within 90 days. Safety outcomes included 
hemorrhage related to clopidogrel and myositis related to 
simvastatin. The median time to stroke outcome was 1 day 
(range 0-62 days). The trial was stopped early due to a fail-
ure to recruit patients at the prespecified minimum enrolment 
rate because of increased use of statins. Some 14 (7.1%) pa-
tients on clopidogrel had a stroke within 90 days compared 
with 21 (10.8%) patients on placebo (risk ratio 0.7 [95% CI 
0.3-1.2]; absolute risk reduction -3.8% [95% CI -9.4 to 1.9]; 
p=0.19). Some 21 (10.6%) patients on simvastatin had a 
stroke within 90 days compared with 14 (7.3%) patients on 
placebo (risk ratio 1.3 [0.7-2.4]; absolute risk increase 3.3% 
[-2.3 to 8.9]; p=0.25). There was no interaction between 
clopidogrel and simvastatin (p=0.64). Two patients on clopi-
dogrel had intracranial hemorrhage compared with none on 
placebo (absolute risk increase 1.0% [-0.4 to 2.4]; p=0.5). 
There was no difference between groups for the simvastatin 
safety outcomes. In conclusion, patients who are at a high 
risk of ischemic stroke immediately after TIA or minor 
stroke, the potential benefit of ischemic stroke reduction 
from combined aspirin and clopidogrel was not offset by 
their hemorrhagic risk. This study did not provide evidence 
of a benefit of simvastatin in this setting. A summary of 
these RCTs in Stroke Rehabilitation in 2007 is presented as 
Table 1. 
Table 1.  Summary of the Randomized Control Trials Undertaken in Stroke Rehabilitation in 2007 
References   Time to Randomi- 
zation Post-Stroke 
Set-up  Sample 
Size 
Main Findings 
Hyperlipidaemia and Stroke 




89  Statin withdrawal was associated with increased risk of 
death or dependency at 90 days. Hence, this treatment 
should be continued in the acute phase of ischemic stroke.  
[3] - Out-patient set-
ting 
984  In middle-aged adults with an FRS of less than 10% and 
evidence of sub-clinical atherosclerosis, rosuvastatin sig-
nificant reduced the rate of progression of maximum CIMT 
over 2 years vs. placebo. 
Diabetes Mellitus and Stroke 
[4] - Out-patient set-
ting 
5238  Pioglitazone was effective in secondary not in primary 
stroke prevention in patients with type 2 diabetes. 




933  Despite significant reduction in the plasma glucose concen-
trations and blood pressure in the GKI group, this interven-
tion did not reduce death or disability rates. Thus maintain-
ing euglycaemia by GKI infusion may have a very small 
effect in reducing death or disability, given that it could not 
be seen in >900 subjects studied. 
Thrombolytic and Stroke 




24  Administration of UA appeared to be safe, decreased lipid 
peroxidation, and prevented an early fall of UA in serum in 
patients treated with rt-PA within 3 hours of stroke onset. 
However, no beneficial clinical effect between the 2 groups 
was noted. 




120  The NEST-1 study indicated that infrared laser therapy was 
a safe and effective treatment for ischemic stroke in hu-
mans when initiated within 24 hours of stroke onset. 




114  The primary end point did not reach statistical significance. 
However, the secondary analyses showed that intra-arterial 
thrombolysis to have the potential to increase excellent 
functional outcome. 
Antiplateltes and Stroke 
[14]   6-months  Out-patient set-
ting 
1068  This study showed that medium intensity oral anticoagula-
tion (target INR range 2.0-3.0) was equally effective as 
aspirin for secondary prevention after transient ischemic 
attack or minor stroke of arterial origin. However, in-
creased bleeding complications in the oral anticoagulation 
group offset its protective effect against ischemic events.
 
[16] -  Out-patient  set-
ting 
973  This study suggests anticoagulation therapy benefits people 
aged over 75 who have atrial fibrillation, unless there are 
contraindications to its use or the patient decides that the 
hemorrhagic risk outweighs its benefit. Randomized Clinical Stroke Trials in 2007  The Open Neurology Journal, 2008, Volume 2    63 
(Table 1). Contd….. 
References   Time to Randomi-
zation Post-Stroke 
Set-up Sample  Size  Main  Findings 
Neuroprotection and Stroke 





607  NXY-059 given within 6 hours of acute ICH was to found a good 
safety and tolerability profile, with no adverse effect on clinical out-
comes but also no benefits. 




3306  NXY-059 was ineffective for the treatment of acute ischemic stroke 
within 6 hours after the onset of symptoms. 




152  This study despite its small sample size and open label suggests mino-
cycline to be of potential functional benefit in acute ischemic stroke. 
Surgery for Stroke 
[22] 92  days  -  16  This trial failed to show a benefit of endovascular treatment for verte-
bral artery stenosis. The reason for lack of benefit of endovascular 
treatment may mainly be due to the small numbers of patients included 
in the study. 
[24]   3 hours  Acute hospitaliza-
tion 
10  Endovascular stent-assisted thrombolysis was found to be a promising 
treatment option in tandem internal carotid and middle cerebral artery 
occlusion with ICA dissection and compared favorably to intravenous 
rtPA alone.  
Unfortunately, the small numbers of individuals studied in these tests 
of surgical interventions for stroke make confident conclusions impos-
sible, despite the potential interest of these approaches. 
Stroke and Subarachnoid Hemorrhage (SAH) 




32  Nicardipine prolonged-release implants reduced the incidence of cere-
bral vasospasm and delayed ischemic deficits and improved clinical 
outcome after severe SAH. 




71  Hydrocortisone supported hypervoluemic therapy was more effective 
than hypervolemic therapy alone in treating SAH induced hyponatre-
mia only. It was unable to relieve symptomatic cerebral vasospasm. 
Depression and Stroke 
[28]  1-2 months  Outpatient setting  188  The Activate-Initiate-Monitor care management model was more ef-
fective than usual care in improving depression outcome measures in 
patients with post-stroke depression.  




411  Motivational interviewing leads to an improvement in patients' mood 3 
months after stroke. 
Bone Loss and Stroke  
[30]  Within 35 days of 
acute stroke 
Hospital based  27  In this study a single infusion of zoledronate in patients with moder-
ately severe strokes protected them from the harmful effects of 
hemiplegia on hip bone density for at least 1 year. 
Deep Vein Thrombosis and Stroke 
[31]  Within 48 hours of 
acute ischemic 
stroke 
 1762  Enoxaparin was preferable to unfractionated heparin for deep venous 
thromboembolism prophylaxis because of its superior clinical benefit 
to risk ratio and convenience of once daily administration.  
Treatment of Transient Ischemic Attack  
[34] -  Population  based  1278  Early initiation of existing treatments (antiplatelets aspirin or clopi-
dogrel, anticoagulant, statin, and an ACE inhibitor) after TIA or minor 
stroke was associated with an 80% reduction in the risk of early recur-
rent stroke. There was no associated increase in the risk of intracerebral 
hemorrhage or other bleeding. 
[35]  Within 24 hours of 
acute stroke 
- 392  In patients who are at a high risk of ischemic stroke immediately after 
TIA or minor stroke, the potential benefit of ischemic stroke reduction 
from combined aspirin and clopidogrel was not offset by their hemor-
rhagic risk. Simvastatin did not reduce the risk of recurrent strokes in 
this patient population. 
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CONCLUSIONS 
  The following conclusions can be drawn from the studies 
summarized here: (1). Aggressive administration of glucose-
potassium-insulin does not benefit acute stroke patients with 
hyperglycaemia. However, pioglitazone reduces the risk of 
recurrent strokes in Type 2 diabetic patients. (2) Nimodipine 
continues to be the prophylactic agent of choice in prevent-
ing vasospasm in patients with SAH because of the ease of 
oral administration. It should be given for a set time period 
of 3-weeks. (3) Warfarin is the agent of choice in elderly 
patients with atrial fibrillation living in the community. (4) 
The drug NXY-059 does not provide clinically significant 
neuroprotection in the clinical settings in which it has been 
tested. (5) Statins decrease morbidity and mortality in acute 
stroke patients already on statins, and are an effective agent 
in primary prevention of acute ischemic stroke. (6) Intra-
arterial Urokinase may be an effective thrombolytic agent 
instead of r-tPA in patients who present between 3 to 6 hours 
after an acute ischemic stroke. (7) Laser therapy is being 
developed as a non-pharmacological thrombolytic modality 
for treatment of stroke. (8) A single dose of Zoledronate, a 
bisphosphonate, helps maintain bone mineral density of the 
affected limbs and prevents fractures. (9) Low-molecular 
weight heparin (enoxaparin) prevents deep vein thrombosis 
as effectively as unfractionated heparin. (10) Stent-assisted 
endovascular thrombolysis is being suggested for internal 
carotid artery dissection with tandem internal carotid and 
middle cerebral artery occlusion and also in vertebral artery 
stenosis. 
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